Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 6/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 0.82 |
| ▸ | MGLL | Q99685 | 1/20 | 0.82 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.65 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.65 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.65 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.65 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.65 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.65 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.65 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.61 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21846444 | 0.90 | CASP3 (0.81) | CASP3FAAHMGLLHDAC3HDAC4 | |
| SCHEMBL18872061 | 0.88 | CASP3 (0.79) | CASP3FAAHMGLLHDAC3HDAC4 | |
| SCHEMBL24327914 | 0.87 | CASP3 (1.00) | CASP3FAAHMGLLHDAC3HDAC4 | |
| SCHEMBL20022708 | 0.87 | CASP3 (0.77) | CASP3FAAHMGLLHDAC3HDAC4 | |
| SCHEMBL17515278 | 0.87 | CASP3 (0.77) | CASP3FAAHMGLLHDAC3HDAC4 | |
| SCHEMBL8222491 | 0.86 | CASP3 (0.75) | CASP3FAAHMGLLHDAC3HDAC4 | |
| SCHEMBL17515279 | 0.83 | CASP3 (1.00) | CASP3FAAHMGLLHDAC3HDAC4 | |
| SCHEMBL24327473 | 0.83 | CASP3 (0.72) | CASP3FAAHMGLLHDAC3HDAC4 | |
| SCHEMBL6550955 | 0.83 | CASP3 (1.00) | CASP3KAT2BKAT2A | |
| SCHEMBL20022707 | 0.82 | CASP3 (0.68) | CASP3FAAHMGLLHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | EMORY UNIVERSITY | 2021-03-04 | — | — | US | claimed |
| EP-3732180-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | Emory University (US) | 2020-11-04 | — | — | EP | claimed |
| WO-2011062864-A2 | INHIBITORS OF NOX ENZYMES AND METHODS OF USE THEREOF | EMORY UNIVERSITY (US) | 2011-05-26 | — | — | WO | claimed |
| EP-3980400-B1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | UNIV EMORY (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | UNIV EMORY (US) | 2025-04-10 | — | — | US | disclosed |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | EMORY UNIVERSITY (US) | 2025-04-08 | — | — | US | disclosed |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | EMORY UNIVERSITY (US) | 2024-07-04 | — | — | US | disclosed |
| CN-117881403-A | Thionucleosides as antiviral agents | 爱莫里大学 | 2024-04-12 | — | — | CN | disclosed |
| CN-117858711-A | Nucleoside and nucleotide analogs as antiviral agents | 爱莫里大学 | 2024-04-09 | — | — | CN | disclosed |
| EP-0506349-A1 | Stabilising solution for lightsensitive silver halide color photographic material, and processing method making use of the stabilizing solution | KONICA CORPORATION (JP) | 1992-09-30 | — | — | EP | disclosed |
| EP-0227358-B1 | HOUSING PACK FOR PHOTOGRAPHIC PROCESSING SOLUTION | KONICA CORPORATION (JP) | 1992-08-12 | — | — | EP | disclosed |
| EP-0476434-A2 | Method for processing silver halide color photographic light sensitive materials | KONICA CORPORATION (JP) | 1992-03-25 | — | — | EP | disclosed |
| EP-0474461-A1 | Method of processing light-sensitive silver halide color photographic material | KONICA CORPORATION (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-4791013-A | STORAGE AND WASTE COMPARTMENTS; OXYGEN BARRIER MEMBRANE | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| US-4778746-A | COLOR DEVELOPING, FIXING, STABILIZATION WITHOUT WASHING | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1988-10-18 | — | — | US | disclosed |
| US-4687731-A | STORAGE STABILITY | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1987-08-18 | — | — | US | disclosed |
| EP-0227358-A2 | Housing pack for photographic processing solution | KONICA CORPORATION (JP) | 1987-07-01 | — | — | EP | disclosed |
| EP-0182566-A2 | Method for processing lightsensitive silver halide color photographic material | KONICA CORPORATION (JP) | 1986-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216413-A1 | THIONUCLEOSIDES AS ANTIVIRAL AGENTS | MTAP, NSUN3, METTL3 | CASP3 182/4885FAAH 3237/4885MGLL 3423/4885 |
| US-20210060051-A1 | COMBINED MODALITIES FOR NUCLEOSIDES AND/OR NADPH OXIDASE (NOX) INHIBITORS AS MYELOID-SPECIFIC ANTIVIRAL AGENTS | NOX1, NOX3, NOX4 | CASP3 1734/4885FAAH 1779/4885MGLL 887/4885 |
| US-12268723-B2 | Peptidomimetics for the treatment of coronavirus and picorna virus infections | ACE2, SARS1, HAVCR2 | CASP3 145/4885FAAH 2088/4885MGLL 2662/4885 |
| US-20250114389-A1 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | PNP, MTAP, NOP2 | CASP3 281/4885FAAH 1588/4885MGLL 2798/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | CASP3 1450/4885FAAH 1558/4885MGLL 635/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | CASP3 310/4885FAAH 1355/4885MGLL 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.